Coronary Computed Tomography Angiography for the Assessment of Sirolimus-Eluting Resorbable Magnesium Scaffold

Tonet, Elisabetta; Cossu, Alberto; Pompei, Graziella; Ruggiero, Rossella; Caglioni, Serena; Mele, Daniela; Boccadoro, Alberto; Micillo, Marco; Cocco, Marta; Raffele, Martina De; Giganti, Melchiore; Biscaglia, Simone; Sgura, Fabio; Preti, Gerlando; Yin, Youbing; Wang, Yi; Quadri, Giorgio; Cerrato, Enrico; Campo, Gianluca

doi:10.3390/life12101612

Cited by 3 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scaffolded segments can be easily distinguished, allowing for quantitative measurements and the calculation of noninvasive FFR. The analysis also indicates a tendency to observe plaque stabilization in the scaffolded segments with fibrosis and calcium [8]. However, further evidence is needed in this setting of BRS patients.…”

Section: Ccta After Scaffold Implantationmentioning

confidence: 77%

See 1 more Smart Citation

Cardiac Computed Tomography in Monitoring Revascularization

Tonet,

Amantea,

Lapolla

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

The use of coronary computed tomography angiography (CCTA) in the setting of stable coronary artery disease is highly recommended for low-risk patients. High-risk patients, such as symptomatic subjects with prior revascularization, are suggested to be investigated with noninvasive functional tests or invasive coronary angiography. CCTA is not considered for these patients because of some well-known CCTA artifacts, such as blooming and motion artifacts. However, new technology has allowed us to obtain images with high spatial resolution, overcoming these well-known limitations of CCTA. Furthermore, the introduction of CT-derived fractional flow reserve and stress CT perfusion has made CCTA a comprehensive examination, including anatomical and functional assessments of coronary plaques. Additionally, CCTA allows for plaque characterization, which has become a cornerstone for the optimization of medical therapy, which is not possible with functional tests. Recent evidence has suggested that CCTA could be used with the aim of monitoring revascularization, both after coronary bypass grafts and percutaneous coronary intervention. With this background information, CCTA can also be considered the exam of choice in subjects with a history of revascularization. The availability of a noninvasive anatomic test for patients with previous coronary revascularization and its possible association with functional assessments in a single exam could play a key role in the follow-up management of these subjects, especially considering the rate of false-positive and negative results of noninvasive functional tests. The present review summarizes the main evidence about CCTA and coronary artery bypass grafts, complex percutaneous coronary intervention, and bioresorbable stent implantation.

show abstract

Section: Ccta After Scaffold Implantationmentioning

confidence: 77%

“…Tonet E et al, 2022 [8] CCTA and FFR-CT in 26 patients treated with Magnesium bioresorbable scaffold. FFR-CT demonstrated to be feasible in scaffolded segments.…”

Section: Ccta After Scaffold Implantationmentioning

confidence: 99%

Cardiac Computed Tomography in Monitoring Revascularization

Tonet,

Amantea,

Lapolla

et al. 2023

JCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…In our study, the use of physiology with IFR to exclude functional stenosis may in part explain the low need for intervention even with anatomic stenosis on imaging [21]. Using noninvasive fractional flow reserve might improve the usefulness of MSCT of BRS in the future [22].…”

Section: Discussionmentioning

confidence: 99%

Long-term multimodality imaging follow-up of ST-segment elevation myocardial infarction patients treated with bioresorbable vascular scaffold: advantages and challenges

Eriksen

Neghabat

Larsen

et al. 2023

Coronary Artery Disease

View full text Add to dashboard Cite

Background: Multislice computed tomography (MSCT) offers a non-invasive method of imaging bioresorbable scaffolds (BRS). Objectives: To investigate the advantages and challenges using MSCT in the follow-up after BRS implantation. Method: The BRS cohort consisting of 31 patients in the ‘BRS in STEMI’ trial was examined by multimodality imaging and followed long-term. Minimum lumen area (MLA) and average lumen area (ALA) were examined 12 and 36 months after BRS implantation with MSCT. Optical coherence tomography (OCT) at 12 months was used as a reference. Results: Measured by MSCT, the mean MLA was 0.05 ± 1.32 mm² (P = 0.85), but ALA was 1.32 (±2.59 mm², P = 0.015) greater than by OCT. ALA and MLA did not change significantly from 12 to 36 months. MSCT identified all cases of restenosis but missed one patient with massive malapposition. Conclusion: Our data support using MSCT in the follow-up after BRS implantation. Invasive investigation should still be considered for patients with unexplained symptoms.

show abstract

“…The SHERPA-MAGIC is an investigator-driven, multicenter, prospective, single-arm study that enrolls consecutive patients undergoing percutaneous coronary intervention (PCI) with implantation of BRS in 18 Italian centers. A summary of the design has been previously reported [8]. The first patient of the SHERPA-MAGIC study was enrolled in December 2017, and both enrollment and follow-up are still ongoing.…”

Section: Methodsmentioning

confidence: 99%